Advanced Solid Tumors Clinical Trials in Los Angeles, California

20 studies are recruiting for advanced solid tumors in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

   The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor?…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   14 in total

   Run by

   Kumquat Biosciences Inc.

   See if you can join NCT07542704 on ClinicalTrials.gov

2. GenSci143 in Participants With Advanced Solid Tumors

   A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - Los Angeles - EDOS, Los Angeles, California

   Locations

   13 in total

   Run by

   Changchun GeneScience Pharmaceutical Co., Ltd.

   See if you can join NCT07252414 on ClinicalTrials.gov

3. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   California Research Institute (CRI), Los Angeles, California

   Locations

   45 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT07262619 on ClinicalTrials.gov

4. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site 125, Los Angeles, California

   Locations

   107 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05914116 on ClinicalTrials.gov

5. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   55 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

6. A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

   The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California

   Locations

   21 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06697197 on ClinicalTrials.gov

7. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

8. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

   The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   4 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT06880549 on ClinicalTrials.gov

9. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

10. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, Los Angeles, California

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

11. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California

    Locations

    181 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

12. Study of FID-022 in Participants With Advanced Solid Tumors

    The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California

    Locations

    3 in total

    Run by

    Fulgent Pharma LLC.

    See if you can join NCT06694480 on ClinicalTrials.gov

13. A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Los Angeles, LLC, Los Angeles, California

    Locations

    33 in total

    Run by

    CStone Pharmaceuticals

    See if you can join NCT06741644 on ClinicalTrials.gov

14. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    9 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07397338 on ClinicalTrials.gov

15. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

16. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

    The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    39 in total

    Run by

    ModernaTX, Inc.

    See if you can join NCT05533697 on ClinicalTrials.gov

17. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Teva Investigational Site 12017, Los Angeles, California

    Locations

    12 in total

    Run by

    Teva Branded Pharmaceutical Products R&D LLC

    See if you can join NCT06480552 on ClinicalTrials.gov

18. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    11 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06413680 on ClinicalTrials.gov

19. SNV4818 in Participants With Advanced Solid Tumors

    This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California

    Locations

    12 in total

    Run by

    Pikavation Therapeutics, Inc.

    See if you can join NCT06736704 on ClinicalTrials.gov

20. A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

    This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars Sinai Medical Center, Los Angeles, California

    Locations

    8 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT05941507 on ClinicalTrials.gov